Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study to Observe Real-life Allocation of Antipsychotics in Acute Inpatient Management of Schizophrenia (RECONNECT-S)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01394601
First received: July 12, 2011
Last updated: November 2, 2012
Last verified: November 2012

July 12, 2011
November 2, 2012
August 2011
December 2011   (final data collection date for primary outcome measure)
Percentage of patients using of atypical antipsychotics.Daily dosage of atypical antipsychotics Mode of administration of atypical antipsychotics. [ Time Frame: up to 6 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01394601 on ClinicalTrials.gov Archive Site
  • Treatment with of only one antipsychotic during the hospitalization.Use of psychometric scales to evaluate the disease symptoms. Relationship between the patient characteristics and the use of antipsychotic during hospitalisation and after discharge [ Time Frame: up to 6 months ] [ Designated as safety issue: No ]
  • Number of antipsychotics used during the hospitalization due to an acutely agitated psychotic episode. Use of treatment concomitant to antipsychotics during the hospitalization [ Time Frame: up to 6 months ] [ Designated as safety issue: No ]
  • Relationship between medication used during the hospitalization and prescribed as maintenance antipsychotic medication upon discharge. [ Time Frame: up to 6 months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
A Study to Observe Real-life Allocation of Antipsychotics in Acute Inpatient Management of Schizophrenia
RECONNECT-S ALPHA: A Non-interventional Study to Observe Real-life Allocation of Antipsychotics in the Acute Inpatient Management of Schizophrenia

RECONNECT-S ALPHA is a multicentre study to observe the management of schizophrenic patients who are hospitalized due to an acutely agitated psychotic episode. The patients should be managed according to normal clinical practice until discharge time. Data will be collected by review of medical records of the hospitalisation prior the study visit. During the study the patients will conduct one visit on the day of their discharge after hospitalisation due to an acutely agitated psychotic episode. On the study visit data on demographics, diagnosis and medical history will be recorded. Data on antipsychotic and concomitant medication will be collected by review of medical records.

RECONNECT-S ALPHA: A non-interventional study to observe real-life allocation of antipsychotics in the acute inpatient management of schizophrenia

Observational
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Retention:   None Retained
Description:

Clinical Practice

Non-Probability Sample

Clinical Practice

Schizophrenia
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
600
December 2011
December 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • male or female patients,
  • 18 years or older,
  • meeting the diagnostic criteria for schizophrenia stated in The Diagnostic and Statistical Manual of Mental Disorders,
  • meeting 4th edition (DSM-IV) criteria hospitalization due to an acutely agitated psychotic episode.

Exclusion Criteria:

  • patient in acutely agitated state upon discharge from the hospital,
  • current participation in any clinical trial,
  • previous enrolment in the present NIS.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Russian Federation
 
NCT01394601
NIS-NRU-ATC-2011/1
No
AstraZeneca
AstraZeneca
Not Provided
Study Director: Alexey Stepanov AstraZeneca
Principal Investigator: Nikolay Govorin Chita State Medical Akademy of Roszdraw
AstraZeneca
November 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP